13 Results for "

monkey plasma

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "monkey plasma" in MCE Product Catalog:

Cat. No.: HY-163689
CAS No.: 1868065-21-7
Synonyms: BI 690517
Vicadrostat (BI 690517) is an orally active aldosterone synthase (aldosterone synthase) inhibitor, with IC50 values of 19 nM, 16 nM, and 18 μM against human, cynomolgus monkey, and rat aldosterone synthase, respectively. Vicadrostat has an in vivo IC50 of 25 nM for aldosterone synthesis. Vicadrostat exhibits high selectivity for cortisol synthase; it reduces aldosterone production and decreases plasma aldosterone levels. Vicadrostat can be used in the research of chronic kidney disease, heart failure, and hypertension .
loading...
    loading...
Cat. No.: HY-NP002O
Synonyms: Cynomolgus monkey serum albumin
Research Areas:  

Others

CMSA Protein (Cynomolgus Monkey Serum Albumin) is a plasma protein derived from cynomolgus monkeys. It is highly homologous to HSA (HY-P1956) and has an extremely high sequence similarity. CMSA Protein mainly regulates blood osmotic pressure and binds or transports hormones, metals, and active compounds.
loading...
    loading...
Cat. No.: HY-P991574
CAS No.: 2643310-75-0
Synonyms: REG-101
MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease .
loading...
    loading...
Cat. No.: HY-159709
CAS No.: 2765519-47-7
Target:  

Liposome

Research Areas:  

Metabolic Disease

VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .
loading...
    loading...
Cat. No.: HY-19848
CAS No.: 839673-52-8
Synonyms: LBM-642
Target:  

PPAR

Research Areas:  

Metabolic Disease

Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
loading...
    loading...
Cat. No.: HY-A0184
CAS No.: 126222-34-2
Synonyms: Ro 42-5892; Ro 42-5892/001
Target:  

Renin

Research Areas:  

Cardiovascular Disease

Remikiren (Ro 42-5892) is an orally active and highly specific renin inhibitor. Remikiren specifically inhibits human reninand human plasma renin with IC50 values of 0.7 and 0.8 nM, respectively. Remikiren also reduces mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys. Remikiren can be used in study of hypertension .
loading...
    loading...
Cat. No.: HY-103537A
CAS No.: 1257396-73-8
Target:  

γ-secretase Amyloid-β

Research Areas:  

Neurological Disease

BIIB042 is a potent, orally active, brain-penetrant, and selective γ-secretase modulator (GSM). BIIB042 reduces Aβ42 and increases Aβ38 levels in cells. BIIB042 significantly reduces brain Aβ42 levels in CF-1 mice and Fischer rats, as well as plasma Aβ42 levels in cynomolgus monkeys. BIIB042 reduces Aβ42 levels and Aβ plaque burden in Tg2576 mice. BIIB042 can be used for alzheimer's disease (AD) research .
loading...
    loading...
Cat. No.: HY-16622A
CAS No.: 1005407-76-0
Target:  

LPL Receptor

Research Areas:  

Others

GSK1842799, an alkyl-substituted biaryl amino alcohol, is a selective S1P1 modulator developed for multiple sclerosis (MS). Upon phosphorylation, GSK1842799-P exhibited subnanomolar S1P1 agonist activity with over 1000-fold selectivity over S1P3. The compound showed good oral bioavailability, rapid in vivo conversion to GSK1842799-P, and significant lymphocyte count reduction at 0.1 mg/kg. It matched FTY720 efficacy at 3 mg/kg in the mouse EAE model and achieved comparable plasma levels to FTY-720 phosphate in cynomolgus monkeys. With favorable ADME, PK/PD properties, and toxicology, GSK1842799 advanced to further clinical development .
loading...
    loading...
Cat. No.: HY-153907
Research Areas:  

Cancer

SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
loading...
    loading...
Cat. No.: HY-118185
CAS No.: 115766-42-2
Target:  

Renin

Research Areas:  

Others

SQ 31844 is a novel renin inhibitor belonging to the imidazolidinol class. This compound, which contains an imidazole ring in its active site binding group, has potent in vitro inhibition of primate renin, but not rat, pig, or dog renin. In conscious, sodium-deprived cynomolgus monkeys, both compounds produced dose-related inhibition of plasma renin activity (PRA) over a dose range of 0.001 to 1.0 μmol/kg, administered intravenously, with complete inhibition observed at the highest dose. However, a reduction in blood pressure was only observed when 10 μmol/kg was administered intravenously or by infusion. In sodium-replete monkeys, SQ 30774 inhibited the increase in arterial blood pressure and PRA following administration of exogenous monkey renin. When the compounds were administered orally at 50 μmol/kg, only SQ 31844 significantly inhibited PRA (80%). In summary, the imidazolidinol renin inhibitors have potent inhibitory effects on renin in vitro and inhibit PRA and reduce arterial blood pressure in vivo.
loading...
    loading...
Cat. No.: HY-117637
CAS No.: 1369357-99-2
Target:  

Oxytocin Receptor

Research Areas:  

Neurological Disease

ALS-I-41 is a novel, potent and selective oxytocin receptor antagonist with the potential to modulate biological activities related to social behavior and mental disorders. ALS-I-41 is being evaluated for behavioral pharmacology experiments in non-human primates and can be administered via intranasal or intramuscular injection. The central nervous system penetration and metabolic rate of ALS-I-41 were studied by mass spectrometry analysis in cerebrospinal fluid and plasma of macaque monkeys .
loading...
    loading...
Cat. No.: HY-119036
CAS No.: 105186-68-3
Target:  

Renin

Research Areas:  

Cardiovascular Disease

KRI-1177 is a competitive, dipeptide human renin inhibitor with a Ki of 0.7 μM and an IC50 of 90 nM. The IC50 of KRI-1177 targeting cynomolgus monkey renin is 680 nM. KRI-1177 acts as an antihypertensive agent, angiotensin inhibitor and plasma renin activity inhibitor, which reduces systemic blood pressure and plasma angiotensin concentration. KRI-1177 exhibits a relatively long-lasting antihypertensive effect in cynomolgus monkeys and can be used for hypertension research .
loading...
    loading...
Cat. No.: HY-129737
CAS No.: 117978-26-4
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

A-62198 is a potent and selective renin inhibitor with antihypertensive activity. A-62198 reduces mean arterial pressure (MAP) in anesthetized, salt-deprived monkeys in a dose-dependent manner. A-62198 induced MAP reduction in normal monkeys that reached statistical significance at the highest dose and significantly inhibited plasma renin activity (PRA) at all doses .
loading...
    loading...
  • 1